Biosimilar Market Trend Overview (January 2025)
Bangladesh's biosimilar market reached approximately $225M in 2024. While that still accounts for only 5% of the country's broader pharmaceutical market, estimated at $4.5B, the segment is expanding at more than 25% annually. Insulin biosimilars represent about 60% of the market, and the product mix is widening to include oncology treatments, EPO products, and growth hormone therapies.
Ahead of Bangladesh's scheduled LDC graduation in 2026, local pharmaceutical companies are accelerating the shift from conventional generics to biosimilars. Major firms such as Incepta, Beximco, and Square are investing heavily in production capacity, while technology transfer partnerships with Korean, Indian, and European companies are becoming more active. For Bangladeshi partners, Korea's Celltrion and Korea Corp Bioepis remain top-priority counterparts because of their global biosimilar track record.
Insulin Biosimilar Market
Bangladesh is one of the world's largest diabetes markets, with roughly 13 million patients, or about 10% of the adult population. Annual insulin demand is estimated at more than $135M, and around 80% of that demand is met by locally produced biosimilar insulin. Incepta's Insul line remains the market leader, followed by Beximco, Square, and Healthcare Pharma.
| Company | Product | Type | Market Share | Production Technology | Partner |
|---|---|---|---|---|---|
| Incepta | Insul R/N/30 | Human insulin | 35% | Recombinant DNA | Danish technology |
| Beximco | Betalin R/N/30 | Human insulin | 20% | Recombinant DNA | In-house development |
| Square | Ansulin R/N/Mix | Human insulin | 15% | Recombinant DNA | Indian technology |
| Healthcare | Mixtard BS | Human insulin | 10% | Recombinant DNA | In-house development |
| Incepta | Insul Glargine | Insulin analogue | 8% | Genetic recombination | Internal R&D |
| Beximco | Betalin Glargine | Insulin analogue | 5% | Genetic recombination | Reviewing Korean collaboration |
Oncology Biosimilar Trends
Oncology biosimilars are currently the fastest-growing segment in Bangladesh. The country records more than 150,000 new cancer cases each year, and demand for biosimilars is rising quickly because originator biologics remain too expensive for much of the market. Biosimilars for trastuzumab, rituximab, and bevacizumab are already being supplied at around 20% to 30% of the price of the original brands. Bangladeshi firms are therefore paying close attention to Celltrion as a potential source of technology transfer for products such as Herzuma and Remsima.
Partnership Opportunities for Korean Biotech Companies
Market Outlook and Risks
| Segment | 2024 | 2025(E) | 2027(E) | 2030(E) | Notes |
|---|---|---|---|---|---|
| Total market | $225M | $280M | $440M | $800M | CAGR 25% |
| Insulin | $135M | $165M | $240M | $400M | more diabetes patients |
| Oncology | $35M | $48M | $90M | $180M | fastest-growing segment |
| Anti-TNF | $25M | $32M | $55M | $100M | rising autoimmune demand |
| EPO | $15M | $18M | $28M | $50M | renal disease demand |
| Other | $15M | $17M | $27M | $70M | growth hormone and others |
Bangladesh's biosimilar market is a high-growth segment that could expand to roughly $800M by 2030. The deadline imposed by LDC graduation is accelerating demand for technology acquisition among local pharmaceutical players, and that creates a timely opening for Korean companies pursuing licensing and technology transfer. In insulin analogues, oncology monoclonal antibodies, and autoimmune biosimilars, Korean firms already hold globally competitive capabilities. Structured cooperation with Bangladeshi partners is therefore not only commercially attractive, but also strategically aligned with the long-term development needs of both markets.